Back to Newsroom

Arrowhead Presents Data Showing Robust Sustained Anti-viral Effects with ARC-520 in Hepatitis B Infected Chimpanzees

PASADENA, Calif.–(BUSINESS WIRE)– Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, presents data at the AASLD Liver Meeting 2015® in an oral presentation and a poster showing that ARC-520, its drug candidate against chronic hepatitis B infection (HBV), leads to robust, sustained anti-viral effects in chimpanzees with chronic HBV. Arrowhead also describes an important new discovery that HBV DNA integrated into the host genome is likely an important source of HBV surface antigen (HBsAg) production, particularly in chimps that are negative for hepatitis B e-antigen (HBeAg). The company plans to present additional data from this study at the 2015 Hep Dart conference in December demonstrating that two of four HBeAg-positive chimps exhibited signs of immune reactivation, which is believed to be a necessary step toward achieving a functional cure of HBV.

Click here to read more